Theratechnologies

In 1993, a new biopharmaceutical company, Theratechnologies, was founded in Montreal, Canada. The company focused on developing treatments for unmet medical needs, specifically for patients with HIV. Two years after its founding, its scientists discovered a compound called tesamorelin, which would become the foundation of its business. For the next 15 years, the company worked on developing this discovery. The major breakthrough came in 2010 when the U.S. FDA approved their drug, EGRIFTA, to treat excess abdominal fat in HIV-infected patients with lipodystrophy. Initially marketed by a partner, Theratechnologies shifted its strategy in 2014, reacquiring the U.S. commercial rights to its own product to become a full-fledged commercial operation. This was followed by the acquisition and 2018 approval of another HIV treatment, Trogarzo. After years of operating and building its portfolio, the company took a major step and listed on the NASDAQ stock exchange in October 2019. This marked a new chapter of public ownership and access to broader capital markets. However, the journey as a public entity reached its final destination in July 2025. After a persistent pursuit, Theratechnologies entered into a definitive agreement to be acquired by CB Biotechnology, an affiliate of Future Pak, for a total potential consideration of $254 million, bringing its story as an independent public company to a close.